Acadia pharmaceuticals enters into an agreement to sell its rare pediatric disease priority review voucher for $150 million

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that it entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher (prv) for $150 million upon the closing of the transaction. acadia was granted the prv in march 2023 following approval by the u.s. food and drug administration (fda) of daybue™ (trofinetide) for the treatment of rett syndrome. daybue was initially licensed by acadia from neuren pharmaceutical.
ACAD Ratings Summary
ACAD Quant Ranking